Research Reports | Market Assessment
June 2014

Non-Small-Cell Lung Cancer (Previously Treated EGFR Wild-Type/Untested) | Decision Base | US/EU | 2014

Of the Several Exciting Agents in Late-Stage Development, Do Any Have the Potential to Dramatically Improve Survival?

Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers; of these lung cancers, approximately 90% are EGFR wild-type/untested. Despite significant advances in the treatment of advanced/metastatic NSCLC in the first-line setting, treatment options for later-line settings have not changed over the past decade. Chemotherapies such as docetaxel (Sanofi’s Taxotere, generics) and pemetrexed (Eli Lilly’s Alimta) and the EGFR inhibitor erlotinib (Genentech/Roche/Chugai/Astellas’s Tarceva) remain the standards of care for EGFR wild-type/untested patients. No targeted agents are available in the second- and later-line settings; therefore, these patients remain difficult to treat. Thus, significant clinical and commercial opportunity remains for novel, highly efficacious, and tolerable therapies.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports